In each episode of Connected With Latham, we discuss ideas, developments, and trends shaping the global economy.
…
continue reading
Hi
…
continue reading
My new mix from my new home in Norway
…
continue reading
Welcome to Marybeth Latham, where amazing things happen. Cover art photo provided by Efe Kurnaz on Unsplash: https://unsplash.com/@efekurnaz
…
continue reading
Come on the journey with me as I explore the long-term focused, value investing field. Listen to annual/quarterly reports, analysis of specific companies and general investing ideas.
…
continue reading
If you are looking to buy or sell a home, get all the information and the latest updates, tips, and tricks from Jeff Latham- your professional washington Real Estate Agent.
…
continue reading
Welcome to the Strive To Be More Podcast! Join Human Rights Lawyer, Public Speaker and Fine Natural Hair ROCKS Founder Lavinia Latham as she shares solid advice with you about life, relationships, and personal growth. Tune in weekly for your personal dose of clarity and motivation to fuel your self-improvement journey.
…
continue reading
1
Episode 86 – Drug Pricing: Takeaways from the Chicago Medicaid Drug Rebate Program Summit
18:25
18:25
나중에 재생
나중에 재생
리스트
좋아요
좋아요
18:25
Manufacturers, government officials, and other stakeholders recently convened in Chicago for the annual Medicaid Drug Rebate Program Summit. In this episode of Connected with Latham, Washington, D.C. associate Danny Machado interviews partner Chris Schott about takeaways from the conference, including thoughts on the new Medicaid regulation that CM…
…
continue reading
1
Episode 85 – Drug Pricing: How The Demise of Chevron Deference and Other Litigation May Impact the Pharmaceutical Industry
21:48
21:48
나중에 재생
나중에 재생
리스트
좋아요
좋아요
21:48
Recent Supreme Court decisions, such as the opinions in Loper Bright Enterprises v. Raimondo and Relentless v. Department of Commerce that overruled the long-standing Chevron doctrine, will likely impact how federal agencies interpret ambiguous statutes when regulating the pharmaceutical industry. And in Securities & Exchange Commission v. Jarkesy,…
…
continue reading
1
Episode 84 – Pro Bono: Shabir Kabiri’s Remarkable Journey from Afghanistan to Asylum in the US
34:22
34:22
나중에 재생
나중에 재생
리스트
좋아요
좋아요
34:22
In this episode of Connected with Latham, we explore the remarkable story of Shabir Kabiri, an Afghan refugee who secured asylum in the United States with the help of a Latham pro bono team. Shabir shares his harrowing journey, his time as a cadet at West Point, and the dangers he faced upon returning home. When Kabul fell to the Taliban in 2021, S…
…
continue reading
1
Episode 83 – Drug Pricing: How Are Payers Responding to the IRA?
29:16
29:16
나중에 재생
나중에 재생
리스트
좋아요
좋아요
29:16
The US healthcare landscape is undergoing significant changes as the Centers for Medicare & Medicaid Services (CMS) continues to implement the Inflation Reduction Act (IRA). One key stakeholder group affected by the IRA drug price negotiations and Medicare Part D redesign are health insurance companies. In this episode of Connected with Latham, we …
…
continue reading
1
Episode 82 – Drug Pricing: Takeaways from the New Orleans Pricing and Contracting USA Conference
17:31
17:31
나중에 재생
나중에 재생
리스트
좋아요
좋아요
17:31
Current developments grabbed much of the spotlight when key industry stakeholders met in New Orleans for the Pricing and Contracting USA Conference. In this episode of Connected With Latham, Washington, D.C. partner Chris Schott and associates Danny Machado and Elisabeth Crusey share their observations from the conference, concluding with four call…
…
continue reading
1
Episode 81 – Drug Pricing: A Look Behind the Curtain of the New ASP Reporting Website and Other Data Collection Portals
23:35
23:35
나중에 재생
나중에 재생
리스트
좋아요
좋아요
23:35
The Centers for Medicare and Medicaid Services (CMS) recently updated its portal for Average Sales Price (ASP) reporting under Medicare Part B. Data collection portals are also essential for manufacturer compliance with the Inflation Reduction Act and for price reporting under the Medicaid Drug Rebate Program. The 340B program operates yet another …
…
continue reading
1
Episode 80 – Energy & Infrastructure: Why is Energy Tech So Attractive to Venture Capital?
26:13
26:13
나중에 재생
나중에 재생
리스트
좋아요
좋아요
26:13
As the energy tech sector continues to mature, venture capital offers an increasingly a viable path to growth as emerging energy tech companies seek to disrupt the energy space, often following a fundraising and growth trajectory similar to software and AI. Energy tech provides opportunities for financial institutions and strategic partners to inve…
…
continue reading
1
Episode 79 – Pro Bono: Rewilding the Scottish Highlands Through Forest Restoration
16:03
16:03
나중에 재생
나중에 재생
리스트
좋아요
좋아요
16:03
Latham’s recently released 2023 Pro Bono Annual Review highlights our public service initiatives around the world, including our ongoing relationship with Trees for Life. This conservation charity is dedicated to rewilding the Scottish Highlands through the restoration of the Caledonian Forest, which supports wildlife found nowhere else in Britain.…
…
continue reading
Following an array of ESG-focused regulation and escalating concerns of greenwashing risks in 2023, the year ahead looks to deliver significant industry developments at a rapid pace. In the UK, the FCA's Sustainability Disclosure Requirements (SDR), investment labelling regime, and anti-greenwashing rule will take effect during 2024. The FCA also p…
…
continue reading
1
Episode 77 – UK FinReg Focus Areas in 2024: Enforcement Against Individuals
8:23
8:23
나중에 재생
나중에 재생
리스트
좋아요
좋아요
8:23
In 2023, the FCA brought more charges for fraud offences against individuals than any other year in the regulator’s history, and secured several convictions related to fraudulent investment schemes. Yet while the FCA has signaled that economic crime is on its radar, recent years have been defined by relative inactivity, as the higher burden of proo…
…
continue reading
1
Episode 76 – UK FinReg Focus Areas in 2024: Regulatory Divergence
17:49
17:49
나중에 재생
나중에 재생
리스트
좋아요
좋아요
17:49
The UK’s announcement of the Edinburgh Reforms in 2022 made clear the government’s intention to chart its own course in rulemaking for the UK financial services sector, and no longer prioritise equivalence with EU legislation. The UK is currently in the process of repealing and restating all retained EU legislation, which will result in divergence …
…
continue reading
1
Episode 75 – UK FinReg Focus Areas in 2024: Enforcement Against Firms
13:24
13:24
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:24
Two new Joint Executive Directors of Enforcement and Market Oversight appointed by the FCA in 2023 will settle into their roles over the year ahead. Following a period of enforcement defined by increased investigations and a willingness to push the envelope of legal interpretation, firms will look toward the coming year to resolve which areas of fo…
…
continue reading
1
Episode 74 – UK FinReg Focus Areas in 2024: Conduct and Culture
13:19
13:19
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:19
With the UK financial services regulators due to publish Policy Statements to their consultations on diversity and inclusion (D&I) this year, conduct and culture remain high on the regulators’ agenda and connect closely to their other regulatory priorities. The regulators have proposed new D&I reporting and disclosure requirements for larger financ…
…
continue reading
1
Episode 73 – UK FinReg Focus Areas in 2024: Artificial Intelligence
13:54
13:54
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:54
The coming year looks poised to act as a pivotal junction for the UK financial services regulators in deciding how to approach the regulation of artificial intelligence (AI), as the financial services industry sees the continued expansion of AI-related capabilities and use cases. To avoid stifling innovation, the UK government plans to take an “agi…
…
continue reading
1
Episode 72 – UK FinReg Focus Areas in 2024: The Edinburgh Reforms
10:18
10:18
나중에 재생
나중에 재생
리스트
좋아요
좋아요
10:18
Since the announcement of the Edinburgh Reforms in 2022, the UK government has made progress on an assortment of measures spanning financial services regulation, with more developments expected in 2024. Though tabled initially as an ambitious suite of reforms, many of the proposals have not been particularly radical in reality. A recent Treasury Co…
…
continue reading
1
Episode 71 – Drug Pricing: A Look Ahead at Trends for 2024
11:48
11:48
나중에 재생
나중에 재생
리스트
좋아요
좋아요
11:48
The pressure and uncertainty of 2023 will likely continue for drug manufacturers in 2024, with the election cycle bringing added scrutiny. At the federal level, continuing implementation of the Inflation Reduction Act, including publication of the so-called negotiated prices, may be disruptive. The states, meanwhile, will likely move forward with t…
…
continue reading
1
Episode 70 – UK FinReg Focus Areas in 2024: Investment Research
17:14
17:14
나중에 재생
나중에 재생
리스트
좋아요
좋아요
17:14
The UK’s decision to scrap compulsory research unbundling, following the final recommendations of the Investment Research Review, marked one of the most striking developments for financial services firms in 2023. Permitting rebundling across the board with no market capitalisation threshold comes as part of a wider approach to reinvigorate UK capit…
…
continue reading
1
Episode 69 – UK FinReg Focus Areas in 2024: Retail Markets – Direction of Travel
13:49
13:49
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:49
As part of the FCA’s continued focus on retail markets, updates to several key regimes are due to progress over the next year. In addition to further implementation of the FCA’s Consumer Duty, the government plans to present detailed proposals on modernising the consumer credit regime, develop proposals to address the “advice gap”, and bring in a n…
…
continue reading
1
Episode 68 – Drug Pricing: Will Agencies Exercise March-In Rights Based on Drug Price?
13:39
13:39
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:39
The National Institute of Standards and Technology (NIST) recently published a draft guidance framework for considering the exercise of march-in rights. Under the Bayh-Dole Act, government agencies can “march in” on patents resulting from government-funded research if the patent licensee is not sufficiently developing the patented invention, based …
…
continue reading
1
Episode 67 – PE Views: The Most Pressing Cybersecurity Considerations For Private Equity
33:59
33:59
나중에 재생
나중에 재생
리스트
좋아요
좋아요
33:59
Cyberattacks targeting well-resourced businesses, especially those with institutional backing, financial support, and deep insurance coverage, have become increasingly prevalent. PE portfolio companies in particular find themselves in the crosshairs of sophisticated attackers — a heightened risk that underscores the need for boards to devote attent…
…
continue reading
1
Episode 66 – UK FinReg Focus Areas in 2024: Primary Markets Reform
13:54
13:54
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:54
For the last three years, UK regulatory authorities have commissioned an array of reviews and consultations to address friction points in the UK’s primary markets, culminating in reforms to the listing regime scheduled to take place in 2024. In addition to simplifying listing segments, these reforms signal a shift to a more disclosure-based regime,…
…
continue reading
1
Episode 65 – PE Views: How Can PE Sponsors Promote Transparency and Successful Fund Raise Amid ESG Scrutiny?
9:51
9:51
나중에 재생
나중에 재생
리스트
좋아요
좋아요
9:51
Regulatory drivers and stakeholder demands have put environmental, social, and governance (ESG) considerations at the forefront of their agendas, with PE firms adopting ESG strategies across funds, investments, due diligence, and portfolio company management. This strong focus has prompted certain stakeholders to argue that ESG factors are receivin…
…
continue reading
1
Episode 64 – Energy & Infrastructure: How Can Companies Avoid Greenwashing Allegations and ESG Litigation Risks?
25:52
25:52
나중에 재생
나중에 재생
리스트
좋아요
좋아요
25:52
As companies feel heightened pressure from stakeholders to adopt environmental, social, and governance (ESG) measures, greenwashing allegations continue to rise in tandem. Complex regulatory environments in the US and across Europe increase the likelihood of enforcement actions and demands for leadership teams to validate their public statements an…
…
continue reading
1
Episode 63 – M&A Views: How Should Deal Teams Navigate a Global Crackdown on Restrictive Covenants?
13:57
13:57
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:57
Regulators in the US, EU, and UK have increasingly scrutinized non-compete and no-poach clauses in employment agreements and M&A deals. The US Federal Trade Commission proposed a rule to ban non-competes in most situations, while several US states seek to implement complete or partial non-compete bans. In Europe, the European Commission and the UK’…
…
continue reading
1
Episode 62 – Has FDA Meaningfully Changed Its Restrictions on Off-Label Communications?
26:26
26:26
나중에 재생
나중에 재생
리스트
좋아요
좋아요
26:26
Following a number of challenges to administrative enforcement on First Amendment grounds, the Food and Drug Administration (FDA) released a new draft guidance document addressing truthful and non-misleading communications regarding product uses not approved or cleared by the FDA. Notably, the document updates the standard for using scientific or m…
…
continue reading
1
Episode 61 – Drug Pricing: New OIG Guidance Reaffirms the Seven Elements of an Effective Compliance Program
12:45
12:45
나중에 재생
나중에 재생
리스트
좋아요
좋아요
12:45
In November, the Department of Health and Human Services’ Office of the Inspector General (OIG) issued new compliance program guidance that affirms OIG’s long-standing focus on the seven elements of an effective compliance program, first published in 2003. In this episode of Connected With Latham, partner Chris Schott and associate Danny Machado ar…
…
continue reading
1
Episode 60 – PE Views: Is the CMA’s Focus on Roll-Up Transactions Here to Stay?
10:28
10:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요
10:28
The UK’s Competition and Markets Authority (CMA) has increasingly asserted its jurisdiction to review private equity buy-and-build transactions, including completed deals, citing competition concerns and protection against perceived threats to consumers. With regulators in the US and elsewhere voicing similar concerns, PE firms and portfolio compan…
…
continue reading
1
Episode 59 – SCOTUS Update: Perez v. Sturgis Secures a Supreme Court Win for Disability Rights
37:08
37:08
나중에 재생
나중에 재생
리스트
좋아요
좋아요
37:08
On March 21, 2023, the US Supreme Court ruled for Miguel Luna Perez, a Latham pro bono client, in Perez v. Sturgis. Perez, who is deaf, was repeatedly denied reasonable accommodations, including a qualified sign-language interpreter, by Sturgis Public Schools and the Sturgis Public Schools Board of Education. Lower courts had held that Perez could …
…
continue reading
1
Episode 58 – FDI Developments: M&A Security Screening in Europe's Fragmented FDI Landscape
19:36
19:36
나중에 재생
나중에 재생
리스트
좋아요
좋아요
19:36
As security interests have become increasingly important in Europe and globally, comprehensive investment control reviews are now an unavoidable element of any cross-border acquisition – with complex legal standards that vary greatly from country to country. In this episode of Connected With Latham, London private equity partner Tom Evans speaks to…
…
continue reading
1
Episode 57 – Drug Pricing: What Trends Emerged from the 2023 Medicaid Drug Rebate Program Summit?
12:12
12:12
나중에 재생
나중에 재생
리스트
좋아요
좋아요
12:12
Not surprisingly, the Inflation Reduction Act (IRA) and its impact on the pharmaceutical industry was a key topic when manufacturers, government officials, and other stakeholders convened in Chicago for the annual Medicaid Drug Rebate Program Summit. The conference’s wide-ranging agenda spotlighted key questions and trends emerging from the Centers…
…
continue reading
1
Episode 56 – M&A Views: Avoiding Buyer’s Remorse in M&A Deals
13:25
13:25
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:25
The buoyant market of 2021 and early 2022 resulted in compressed deal timelines and frenzied competition, causing many deals to be signed with fewer buyer protections and less information about target businesses. The aftermath of this M&A surge has seen a rise in post-closing discoveries of target company issues, compounded by ongoing macroeconomic…
…
continue reading
1
Episode 55 – Insurtech: What Should Startups Do After Receiving FCA Authorization?
8:37
8:37
나중에 재생
나중에 재생
리스트
좋아요
좋아요
8:37
Startups in the insurtech sector have found increasing success in obtaining authorization from the Financial Conduct Authority (FCA). Yet the requirements to achieve such success can complicate a startup’s operations, from early pressure on resources and staffing to regulatory obligations. In this episode of Connected With Latham, partner Shing Lo …
…
continue reading
1
Episode 54 – Drug Pricing: Focus on Best Price — CMS Proposed Rule, Inflation Reduction Act
13:17
13:17
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:17
In a proposed rule issued earlier this summer, the Centers for Medicare & Medicaid Services (CMS) suggested expanding the scope of combining, or stacking, discounts when determining best price. Meanwhile, the Inflation Reduction Act amended the statutory best price definition to include maximum fair prices negotiated under CMS’s new Medicare price …
…
continue reading
1
Episode 53 – Energy & Infrastructure: Can Sustainable Finance Fuel the Energy Transition?
18:05
18:05
나중에 재생
나중에 재생
리스트
좋아요
좋아요
18:05
As more energy and infrastructure companies commit to sustainability targets amidst the energy transition, sustainable finance options, such as green bonds, increasingly offer a viable alternative to traditional financing for projects across the globe. Still, with enhanced regulatory scrutiny, concerns of greenwashing, and ESG-related litigation, c…
…
continue reading
1
Episode 52 – Drug Pricing: Could a Single Reference Price Apply Across a Therapeutic Class?
11:16
11:16
나중에 재생
나중에 재생
리스트
좋아요
좋아요
11:16
The policy conversation related to reimbursement rates for drugs has recently turned toward pricing for entire therapeutic classes, rather than assessing the value of an individual drug. Two recent developments emphasize a growing call for establishing a single payment rate for therapeutic classes: the Medicare Payment Advisory Commission’s (MedPAC…
…
continue reading
1
Episode 51 – Drug Pricing: Final IRA Price Negotiation Guidance – How CMS Addressed the Part D/B Problem
10:53
10:53
나중에 재생
나중에 재생
리스트
좋아요
좋아요
10:53
The Centers for Medicare & Medicaid Services (CMS) recently published its final guidance to implement the drug price negotiation provisions of the Inflation Reduction Act. While retaining the active moiety/active ingredient approach to identifying drugs subject to negotiation, CMS now will only include those products with historic or likely Part D …
…
continue reading
1
Episode 50 – PE Views: Under New Reforms, Is the Customer Always Right?
12:48
12:48
나중에 재생
나중에 재생
리스트
좋아요
좋아요
12:48
Consumer-facing companies face an increasingly complex UK regulatory landscape as multiple regulators place the spotlight on consumer rights and protections. A raft of new legislation focused on “good consumer outcomes” is set to impact businesses and PE sponsors, heightening enforcement and censure risks including fines, public sanctions, and cons…
…
continue reading
1
Episode 49 – PE Views: Will Greenwashing Rain on the UK PE Parade?
17:29
17:29
나중에 재생
나중에 재생
리스트
좋아요
좋아요
17:29
Amid concerns of exaggerated or misleading sustainability claims, the UK Financial Conduct Authority’s (FCA) proposal for new labelling and disclosure rules for sustainability claims has put a spotlight on a growing range of greenwashing risks. Private equity firms should evaluate the latest wave of new rules and requirements being enacted and cont…
…
continue reading
1
Episode 48 – M&A Views: Will UK-Bound M&A Need to Come to US Terms?
11:53
11:53
나중에 재생
나중에 재생
리스트
좋아요
좋아요
11:53
Global M&A deal volumes have dipped at the start of Q1 2023, yet UK-bound M&A activity is expected to be one of the year’s highlights as overseas buyers seek out attractively priced British public and private targets. Within this activity, US buyers’ deal term preferences are likely to impact private UK M&A. So transatlantic dealmakers will find it…
…
continue reading
1
Episode 47 – Real Estate Realities in Europe: Expensive Money and the Power of Private Equity
12:20
12:20
나중에 재생
나중에 재생
리스트
좋아요
좋아요
12:20
As interest rates soar to the highest rates in a decade, European real estate buyers and sellers are struggling to makes economic deals — transaction volumes in Europe fell by 44% in the last year. Despite a comparatively down year in fundraising for real estate funds, some €80 billion has already been raised for real estate acquisitions, in contra…
…
continue reading
1
Episode 46 – PE Views: PE Must Strike the Right Balance With Unions
12:30
12:30
나중에 재생
나중에 재생
리스트
좋아요
좋아요
12:30
Widespread economic pressure — including pay, inflation, and the ongoing cost of living crisis — has increased union visibility. As the number of workers interested in union membership grows and the frequency of strikes surges in the UK and elsewhere, PE deal teams should remain mindful of the presence and role of unions in M&A. In this episode of …
…
continue reading
Insurtech has become a darling of both traditional players in the insurance market and disruptive fintech operations. The coming year looks to continue this trend, with companies looking to insurtech as a venue for penetrating new markets. Yet as insurtech’s attractiveness continues to grow, potential investors will need to navigate a highly regula…
…
continue reading
1
Episode 44 – PE Views: Private Equity Looks to Share-Based Schemes to Incentivise Non-Managerial Staff
13:16
13:16
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:16
Equity and co-investment opportunities have long served as tried and tested strategies for buyout firms seeking to incentivise management and align key management interests with those of the PE sponsor. However, PE sponsors in the US have recently received credit for extending share ownership opportunities beyond key management — and in some cases,…
…
continue reading
1
Episode 43 – Energy & Infrastructure: The Drivers and Opportunities of Asia’s Digital Infrastructure Boom
19:27
19:27
나중에 재생
나중에 재생
리스트
좋아요
좋아요
19:27
Digital infrastructure has become a basic component of all economies, and growth economies in particular. For many countries in Asia, digital infrastructure will drive development as much as power and water supply – particularly in Singapore, Indonesia, Vietnam, and India, which have the potential to be serious players in the global tech industry. …
…
continue reading
1
Episode 42 – PE Views: Has Rethinking Cannabis Sparked PE Interest?
9:28
9:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요
9:28
Not long ago, the prospect of significant PE investment in the cannabis industry would have been unthinkable for many. However, recent regulatory and legal developments have created opportunities for medical cannabis businesses and legalised new non-medical cannabis applications in many jurisdictions. Buyout firms have shown significant appetite fo…
…
continue reading
1
Episode 41 – PE Views: Why Do Music Deals Sound So Attractive to PE?
13:39
13:39
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:39
Music deals, particularly the acquisition of rights to songs and recordings by popular music artists, remain attractive investments for PE. The continued popularity of global streaming services and the music rental economy have helped to reduce the threat of online piracy, made revenues easier to track and predict, and ensured that strong revenues …
…
continue reading
1
Episode 40 – PE Views: Could PE Benefit From the Universal Adoption of “Super Senior” RCFs in Leveraged Financings?
10:43
10:43
나중에 재생
나중에 재생
리스트
좋아요
좋아요
10:43
Undrawn revolving credit facilities (RCFs) serve as essential parachutes to private equity. They are a backup in the event of mismatches in the working capital cycle, they provide comfort for a rainy day, and they preserve swift access to deal-making when other financing sources are unavailable, or less easily accessible. The COVID-19 pandemic clea…
…
continue reading
1
Episode 39 – New FDA Commissioner Dr. Califf: What His Appointment Means for the Regulated Industry and What to Watch for in 2022
20:05
20:05
나중에 재생
나중에 재생
리스트
좋아요
좋아요
20:05
Now that the US Senate has confirmed Dr. Robert Califf as Commissioner of the US Food and Drug Administration, a position he held briefly in the Obama Administration, we turn to the priorities and perspective he is likely to bring to the agency. Making big data, including from electronic health records, useful for research and sufficient to support…
…
continue reading
1
Episode 38 – PE Views: How are ESG Regulatory Reforms and Investor Focus Shaping the Market?
16:07
16:07
나중에 재생
나중에 재생
리스트
좋아요
좋아요
16:07
Market sentiment and the increasing importance of environmental, social, and governance (ESG) to firms’ competitiveness across the market, combined with wide-ranging and rapidly developing ESG regulatory reforms, are driving increased focus on ESG at both LP and GP levels across Europe. As a result, the market is showing demand for enhanced diligen…
…
continue reading
1
Episode 37 – Energy & Infrastructure: What’s Behind The Wave of ESG Shareholder Activism?
24:28
24:28
나중에 재생
나중에 재생
리스트
좋아요
좋아요
24:28
After years of garnering little attention, environmental, social, and governance (ESG) matters are now top-of-mind for institutional investors – and are beginning to drive activist campaigns. What is behind this wave of ESG activism? And what can companies do to prepare for the possibility of an ESG-driven activist campaign? In this episode of Conn…
…
continue reading